INTRODUCTION
Diffuse bleeding is a common problem after cardiac operations using cardiopulmonary bypass (CPB). CPB causes platelet dysfunction, decreased clotting factors, and fibrinolysis. [1] [2] [3] Significant fibrinolysis after CPB is reflected by increased concentrations of plasmin and fibrin degradation products.
[4] Nearly 2%-6% of patients need re-exploration for excessive mediastinal bleeding after coronary artery bypass graft (CABG) surgery [5] [6] [7] which is responsible for 10.3% of all CABG surgery deaths. Almost 25%-40% of significant postbypass bleedings are caused by fibrinolysis. [8] There are several antifibrinolytic drugs such as aminocaproic acid, [9] aprotinin, [10] and tranexamic acid (TA). [11] [12] [13] [14] Their systemic usage has been shown to reduce postbypass bleeding but may be associated with thromboembolic complications lack of coagulation and bleeding disorders, and lack of liver and kidney disease. [20] Exclusion criteria were complex surgery, emergency surgery, anticoagulation therapy before surgery, and having hemoglobin lower than 8 g per deciliter before surgery. Written consent form was obtained from patients. This study was registered with IRCT2016071628945N1q number.
One hundred and twenty-six patients undergone CABG, who had been diagnosed by a cardiologist and based on inclusion and exclusion criteria were included in the study. The patients were divided into two groups of intervention and control (63 cases in control group and 63 cases in intervention group). One hundred and twenty-five patients completed the study; 62 from TA group and 63 from normal saline group. Random assignment was performed by dividing patients into even and odd year of birth; even years were intervention group and odd years were control group [ Figure 1 ].
The anesthetic management and conduct of CPB were standardized. The patients were premedicated using nitrazepam 0.1 mg/kg tablet the night of the operation and morphine 0.15 mg/kg intramuscular ½ h before operation. Induction was done using fentanyl 2-5 ug/kg, propofol 1-2 mg/kg, and pancuronium 0.1 mg/kg. Anesthesia was maintained using sevoflurane 0.5%-1%, pancuronium 0.06 mg/kg, and fentanyl 1-2 ug/kg during CPB time. All patients received heparin 300 units/kg before CPB to achieve target activated clotting time (ACT) of ≥480 s. During CPB, extra heparin was given as needed to maintain the target ACT. [20] After completion of the operation and suction all fluids and blood in the wound, for intervention group, TA (TRANEXIP, Capiantamin Company) with dose of 1 g diluted in 100 mL of saline, and for the control group, 100 mL of saline was poured into pericardial space and then the chest tube was clamped and the wound was closed and the patient was transferred to the ICU and then chest tubes were opened. The primary outcome measure for our study was the 1 st day bleeding amount in the chest bottle, total amount of bleeding in 48 h, and the amount of blood transfusion. Two different technicians collecting the same data separately and the surgeon were not informed about the groups.
Statistical analysis
Analysis was done using descriptive statistics such as mean and standard deviation and analytical statistics such as t-test, Mann-Whitney test, and Pearson and Spearman correlation coefficient by SPSS software version 22. P < 0.05 was considered statistically significant.
RESULTS
Both groups were matched in terms of age (P = 0.585) and gender (P = 0.66) [ Table 1 ]. One patient was dropped out and finally, 125 patients completed the study. The age range of patients in the intervention group was 41-79 years and control group 40-78 years. In intervention group, 77.8% (n = 49) of patients were male and in control group was 81% (n = 51). Moreover, serious adverse event were not observed in both groups.
Furthermore, body mass index (BMI) and ejection fraction [ Tables 1 and 2 ] did not show a significant differences between the groups (P = 0.188 and P = 0.463, respectively). As obtained, clamp time was significantly more in intervention group as compared to control group (56.66 vs. 49.46 min) (P = 0.01). Surgery duration and bypass time in both groups were same to each other and no differences were obtained (P = 0.257 and P = 0.166, respectively).
In Table 2 , it is shown that the mean of bleeding amount in first 24 h after surgery in intervention group was 567.42 ml and in control group was 564.44 ml (P = 0.894). Moreover, the mean of bleeding amount in second 24 h after surgery and totally in intervention group was 213.07 ml and 780.48 ml, respectively, and in control group was 155.71 ml and 665.4 ml, respectively (P = 0.327 and P = 0.033, respectively); it shows that the amount of bleeding had no statistically difference in both groups. Furthermore, the mean of blood transfusion and hemoglobin decreasing did not show a significant correlation between the groups (P = 0.708 and P = 0.263, respectively).
As obtained, the risk factors for massive bleeding in patients undergoing CABG surgery were BMI (correlation coefficient = −0.239, P = 0.007), clamp time (correlation coefficient = 0.213, P = 0.018), and surgery duration (correlation coefficient = 0.292, P = 0.001), which shows that BMI had reverse correlation with bleeding volume, whereas clamp time and surgery duration had positive and significant correlation with bleeding volume.
DISCUSSION
Intravenous use of TA has proved to be effective in decreasing postoperative bleeding of CABG surgery. [11, 21, 22] On the other hand, Ovrum et al. have shown no significant decrease in blood loss with intravenous TA usage and also have shown possible increased risk of thromboembolic complications including graft closure with antifibrinolytic usage after CABG. [15] The concept of using topical usage of antifibrinolytic agents was studied in several trials to prevent possible thromboembolic complications of their intravenous usage and has published decreased postoperative bleeding with topical usage of TA. [18, 20] Bonis et al. poured 1 g TA in 100 mL of saline solution in mediastinal cavity of twenty patients and compared them with twenty control patients and showed significant reduction in postoperative bleeding. [18] Fawzy et al. compared 19 patients receiving 1 g TA diluted in 100 ml normal saline with 19 control group patients and resulted in significant reduction in postoperative blood loss without adding extra risk to the patients. [20] In our study, larger numbers of patients (125 patients) were included and the effectiveness of topical usage of 1 g TA diluted in 100 ml normal saline in preventing post-CABG blood loss was assessed. The amount and concentration of TA used in our study were nearly similar to other studies. The study showed no difference in postoperative blood loss in either first or second 24 h. Furthermore, blood transfusion was not decreased in the study group.
CONCLUSION
We do not recommend topical usage of 1 g TA diluted in 100 ml normal saline for decreasing blood loss in on-pump CABG patients. More studies are needed to clear why there are different results of different studies. Furthermore, it is recommended to apply larger amounts of local TA to assess its effectiveness in decreasing postoperative blood loss.
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